PRL and small cell lung carcinoma: The results showed that bladder cancer (hsa:05219), platinum drug resistance (hsa:01524), prolactin signaling pathway (hsa:04917), small cell lung cancer (hsa:05222), IL-17 signaling pathway (hsa:04657), and TNF signaling pathway (hsa:04668) were highly enriched (Figure 8).